Superworth

Vericel PE ratio VCEL

Share price divided by earnings per share over the last twelve months, since 2021.

Today, Nov 2, 2026
88.1×
5-year median
157×
Against its 5-year history
13th
percentile: 0 is its lowest day, 100 its highest
5-year range
80.6× to 313×
Peer median
29.6×

Vericel's PE ratio is 88.1× as of Nov 2, 2026: a share price of $40.51 against $0.46 of earnings per share over the last twelve months.

That is below its 5-year median of 157×, lower than on 87% of days in the last 5 years.

Over that time it ranged from 80.6× in May 2026 to 313× in Sep 2021.

The median for 8 biotech stocks of a similar size is 29.6×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far88.1×80.6×161×
2025157×150×309×
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021256×256×313×

Against its peers

Companies in Biotechnology nearest Vericel's size, closest first, today.

CompanyPE ratio
VCELVericel88.1×
ADMAAdma Biologics15.8×
MGTXMeiraGTx13.1×
KRYSKrystal Biotech37.1×
RGENRepligen237×
TECHBIO-TECHNE63.2×
HALOHalozyme Therapeutics38.5×
NBIXNeurocrine Biosciences21.3×
EXELExelixis22.1×
Peer median29.6×

Where Vericel ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Vericel

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.